'Least Burdensome' Comment Deadline Delayed By US FDA
Executive Summary
The deadline has been bumped back to mid-March following a request from industry trade group AdvaMed.
You may also be interested in...
'Least Burdensome' Supersized? Draft Guidance Outlines An Expanded View Of The US FDA Concept
The US agency issued a draft guidance that brings the 20-year old concept of "least burdensome" in medical device regulation to all corners of the device center's activities.
Senate Adopts Cures Bill By Big Margin; FDA Could Tap $20m More In 2017
The Senate approved the same 21st Century Cures bill passed by the House last week on a 94-5 tally; the bill is expected to be quickly signed by President Obama. Provisions for extra dollars for FDA in the bill means that even with a plan by Congress to adopt a continuing resolution this week freezing FDA funding until April 28, the agency can rely on an additional $20 million set aside for it in Cures in the new year.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.